100 related articles for article (PubMed ID: 19939455)
1. Distinct metabolism of cyclic adenosine monophosphate in regulatory and helper CD4+ T cells.
Bazhin AV; Kahnert S; Kimpfler S; Schadendorf D; Umansky V
Mol Immunol; 2010 Jan; 47(4):678-84. PubMed ID: 19939455
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells.
Leveque L; Deknuydt F; Bioley G; Old LJ; Matsuzaki J; Odunsi K; Ayyoub M; Valmori D
J Immunother; 2009; 32(2):101-8. PubMed ID: 19238008
[TBL] [Abstract][Full Text] [Related]
3. IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.
Nishihara M; Ogura H; Ueda N; Tsuruoka M; Kitabayashi C; Tsuji F; Aono H; Ishihara K; Huseby E; Betz UA; Murakami M; Hirano T
Int Immunol; 2007 Jun; 19(6):695-702. PubMed ID: 17493959
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression.
Chouaib S; Welte K; Mertelsmann R; Dupont B
J Immunol; 1985 Aug; 135(2):1172-9. PubMed ID: 2989362
[TBL] [Abstract][Full Text] [Related]
5. Regulation of cAMP-responsive enhancer binding proteins during cell cycle progression in T lymphocytes stimulated by IL-2.
Feuerstein N; Huang D; Hinrichs SH; Orten DJ; Aiyar N; Prystowsky MB
J Immunol; 1995 Jan; 154(1):68-79. PubMed ID: 7995960
[TBL] [Abstract][Full Text] [Related]
6. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro.
George TC; Bilsborough J; Viney JL; Norment AM
Eur J Immunol; 2003 Feb; 33(2):502-11. PubMed ID: 12645949
[TBL] [Abstract][Full Text] [Related]
7. Activation of the CD3/T cell receptor (TcR) complex or of protein kinase C potentiate adenylyl cyclase stimulation in a tumoral T cell line: involvement of two distinct intracellular pathways.
Bihoreau C; Heurtier A; Enjalbert A; Corvaïa N; Bensussan A; Degos L; Kordon C
Eur J Immunol; 1991 Nov; 21(11):2877-82. PubMed ID: 1657616
[TBL] [Abstract][Full Text] [Related]
8. Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways.
Butler JJ; Mader JS; Watson CL; Zhang H; Blay J; Hoskin DW
J Cell Biochem; 2003 Aug; 89(5):975-91. PubMed ID: 12874832
[TBL] [Abstract][Full Text] [Related]
9. Modulation of cardiac cyclic AMP metabolism by adenosine receptor agonists and antagonists.
Ma H; Green RD
Mol Pharmacol; 1992 Nov; 42(5):831-7. PubMed ID: 1331765
[TBL] [Abstract][Full Text] [Related]
10. Costimulatory signals modulate the antiproliferative effects of agents that elevate cAMP in T cells.
Bartik MM; Bauman GP; Brooks WH; Roszman TL
Cell Immunol; 1994 Oct; 158(1):116-30. PubMed ID: 8087859
[TBL] [Abstract][Full Text] [Related]
11. Suppression of lipopolysaccharide-induced tumor necrosis factor-alpha generation from human peripheral blood monocytes by inhibitors of phosphodiesterase 4: interaction with stimulants of adenylyl cyclase.
Seldon PM; Barnes PJ; Meja K; Giembycz MA
Mol Pharmacol; 1995 Oct; 48(4):747-57. PubMed ID: 7476903
[TBL] [Abstract][Full Text] [Related]
12. Different effect of prostaglandin E2 on B-cell activation by two distinct B-cell differentiation factors, B151-TRF1/IL-5 and B151-TRF2: selective inhibition of B151-TRF2-induced antibody response through increases in intracellular cyclic AMP levels.
Ishihara K; Ono S; Takahama Y; Hirayama F; Hirano H; Itoh K; Dobashi K; Murakami S; Katoh Y; Yamaguchi M
Immunology; 1989 Oct; 68(2):154-62. PubMed ID: 2553585
[TBL] [Abstract][Full Text] [Related]
13. [Role of phosphodiesterase in the changes of cyclic adenosine-3',5'-monophosphate in the rabbit jejunal mucosa after treatment with cholera enterotoxin].
Iurkiv VA; Melikhov VI
Vopr Med Khim; 1982; 28(5):123-7. PubMed ID: 6294992
[TBL] [Abstract][Full Text] [Related]
14. Valproate activates phosphodiesterase-mediated cAMP degradation: relevance to C6 glioma G1 phase progression.
Gallagher HC; Bacon CL; Odumeru OA; Gallagher KF; Fitzpatrick T; Regan CM
Neurotoxicol Teratol; 2004; 26(1):73-81. PubMed ID: 15001216
[TBL] [Abstract][Full Text] [Related]
15. Regulation of CD4+CD25+ regulatory T cell activity: it takes (IL-)two to tango.
Scheffold A; Hühn J; Höfer T
Eur J Immunol; 2005 May; 35(5):1336-41. PubMed ID: 15827965
[TBL] [Abstract][Full Text] [Related]
16. IL-2 activation of STAT5 enhances production of IL-10 from human cytotoxic regulatory T cells, HOZOT.
Tsuji-Takayama K; Suzuki M; Yamamoto M; Harashima A; Okochi A; Otani T; Inoue T; Sugimoto A; Motoda R; Yamasaki F; Nakamura S; Kibata M
Exp Hematol; 2008 Feb; 36(2):181-92. PubMed ID: 18023521
[TBL] [Abstract][Full Text] [Related]
17. [Activation of adenylate cyclase system enzymes and lysosomal acid phosphatase in target cells interacting with T-killer cells].
Sashchenko LP; Kupriianova TA; Memelova LV; Bykovskaia SN; Gnuchev NV
Mol Biol (Mosk); 1985; 19(1):119-31. PubMed ID: 2984545
[TBL] [Abstract][Full Text] [Related]
18. Repression of cyclic adenosine monophosphate upregulation disarms and expands human regulatory T cells.
Klein M; Vaeth M; Scheel T; Grabbe S; Baumgrass R; Berberich-Siebelt F; Bopp T; Schmitt E; Becker C
J Immunol; 2012 Feb; 188(3):1091-7. PubMed ID: 22190184
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory T cells.
Ren X; Ye F; Jiang Z; Chu Y; Xiong S; Wang Y
Cell Death Differ; 2007 Dec; 14(12):2076-84. PubMed ID: 17762882
[TBL] [Abstract][Full Text] [Related]
20. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats.
Rott O; Cash E; Fleischer B
Eur J Immunol; 1993 Aug; 23(8):1745-51. PubMed ID: 8393796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
